000130330 001__ 130330
000130330 005__ 20240228143425.0
000130330 0247_ $$2doi$$a10.18632/oncotarget.10729
000130330 0247_ $$2pmid$$apmid:27449098
000130330 0247_ $$2pmc$$apmc:PMC5312160
000130330 0247_ $$2altmetric$$aaltmetric:10111986
000130330 037__ $$aDKFZ-2017-05409
000130330 041__ $$aeng
000130330 082__ $$a610
000130330 1001_ $$0P:(DE-HGF)0$$aPickl, Julia M A$$b0$$eFirst author
000130330 245__ $$aAgo-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression.
000130330 260__ $$a[S.l.]$$bImpact Journals LLC$$c2016
000130330 3367_ $$2DRIVER$$aarticle
000130330 3367_ $$2DataCite$$aOutput Types/Journal article
000130330 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522136125_11125
000130330 3367_ $$2BibTeX$$aARTICLE
000130330 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130330 3367_ $$00$$2EndNote$$aJournal Article
000130330 520__ $$aProstate cancer is a heterogeneous disease. MiR-375 is a marker for prostate cancer progression, but its cellular function is not characterized. Here, we provide the first comprehensive investigation of miR-375 in prostate cancer. We show that miR-375 is enriched in prostate cancer compared to normal cells. Furthermore, miR-375 enhanced proliferation, migration and invasion in vitro and induced tumor growth and reduced survival in vivo showing that miR-375 has oncogenic properties in prostate cancer. On the molecular level, we provide the targetome and genome-wide transcriptional changes of miR-375 expression by applying a generalized linear model for Ago-RIP-Seq and RNA-Seq, and show that miR-375 is involved in tumorigenic networks and Polycomb regulation. Integration of tissue and gene ontology data prioritized miR-375 targets and identified the tumor suppressor gene CBX7, a member of Polycomb repressive complex 1, as a major miR-375 target. MiR-375-mediated repression of CBX7 was accompanied by increased expression of its homolog CBX8 and activated transcriptional programs linked to malignant progression in prostate cancer cells. Tissue analysis showed association of CBX7 loss with advanced prostate cancer. Our study indicates that miR-375 exerts its tumor-promoting role in prostate cancer by influencing the epigenetic regulation of transcriptional programs through its ability to directly target the Polycomb complex member CBX7.
000130330 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000130330 588__ $$aDataset connected to CrossRef, PubMed,
000130330 7001_ $$0P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aTichy, Diana$$b1$$udkfz
000130330 7001_ $$0P:(DE-He78)cd1568106ba01cc0741f464d15267a9b$$aKuryshev, Vladimir$$b2$$udkfz
000130330 7001_ $$aTolstov, Yanis$$b3
000130330 7001_ $$aFalkenstein, Michael$$b4
000130330 7001_ $$aSchüler, Julia$$b5
000130330 7001_ $$0P:(DE-HGF)0$$aReidenbach, Daniel$$b6
000130330 7001_ $$0P:(DE-He78)2f34b89d62d5e5c651aa1e683844b092$$aHotz-Wagenblatt, Agnes$$b7$$udkfz
000130330 7001_ $$aKristiansen, Glen$$b8
000130330 7001_ $$aRoth, Wilfried$$b9
000130330 7001_ $$aHadaschik, Boris$$b10
000130330 7001_ $$aHohenfellner, Markus$$b11
000130330 7001_ $$aDuensing, Stefan$$b12
000130330 7001_ $$0P:(DE-HGF)0$$aHeckmann, Doreen$$b13
000130330 7001_ $$0P:(DE-He78)7483734fd8ab316391aa604c95f0e98a$$aSültmann, Holger$$b14$$eLast author$$udkfz
000130330 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.10729$$gVol. 7, no. 37, p. 59589 - 59603$$n37$$p59589 - 59603$$tOncoTarget$$v7$$x1949-2553$$y2016
000130330 909CO $$ooai:inrepo02.dkfz.de:130330$$pVDB
000130330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000130330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cd1568106ba01cc0741f464d15267a9b$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000130330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000130330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2f34b89d62d5e5c651aa1e683844b092$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000130330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000130330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7483734fd8ab316391aa604c95f0e98a$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000130330 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000130330 9141_ $$y2016
000130330 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000130330 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130330 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130330 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130330 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130330 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130330 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130330 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130330 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000130330 9201_ $$0I:(DE-He78)B063-20160331$$kB063$$lKrebsgenomforschung$$x0
000130330 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000130330 9201_ $$0I:(DE-He78)W180-20160331$$kW180$$lBioinformatik (HUSAR)$$x2
000130330 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000130330 980__ $$ajournal
000130330 980__ $$aVDB
000130330 980__ $$aI:(DE-He78)B063-20160331
000130330 980__ $$aI:(DE-He78)C060-20160331
000130330 980__ $$aI:(DE-He78)W180-20160331
000130330 980__ $$aI:(DE-He78)L101-20160331
000130330 980__ $$aUNRESTRICTED